Gene Transplant Market Report 2026

The gene transplant market size has grown rapidly in recent years. It will grow from $4.13 billion in 2025 to $4.67 billion in 2026 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to advancements in cell and gene therapy research, increasing clinical trial activity, growth in rare disease treatment programs, rising investment in regenerative medicine, improved gene delivery technologies.

The gene transplant market size is expected to see rapid growth in the next few years. It will grow to $7.57 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing regulatory approvals for gene therapies, rising demand for personalized oncology treatments, expansion of allogeneic therapy pipelines, growing investment in gene therapy manufacturing, increasing collaboration between biotech firms and hospitals. Major trends in the forecast period include increasing adoption of autologous gene therapies, rising use of car-t cell treatments, growing development of off-the-shelf gene therapies, expansion of clinical gene transplant trials, enhanced focus on personalized genetic treatments.

The increasing adoption of gene therapy is expected to propel the growth of the gene transplant market going forward. Gene therapy involves modifying or manipulating genes to treat or prevent disease. Its growing adoption is driven by advances in delivery technologies that enable safe, efficient, and targeted delivery of genetic material into cells. Gene therapy enhances the management of genetic disorders by providing targeted treatments that correct or replace faulty genes, offering solutions for conditions previously considered untreatable. It helps slow disease progression and alleviate symptoms by addressing underlying genetic causes, improving patient outcomes and quality of life. For instance, in December 2024, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, the Food and Drug Administration (FDA) approved six gene therapy products in 2023, compared to five approvals in 2022. Therefore, the rising adoption of gene therapy is contributing to the growth of the gene transplant market.

Leading companies operating in the gene transplant market are focusing on advancing solutions such as automated cloning platforms to enhance efficiency, improve precision, and accelerate the development of gene therapies. Automated cloning platforms are systems designed to automatically isolate and expand single cells into monoclonal populations, improving consistency, accuracy, and speed for gene transplant and therapeutic applications. For example, in November 2024, iotaSciences Ltd., a UK-based life sciences technology company, launched the XT Single-Cell Cloning Platform, an automated cloning solution. The platform integrates automated microfluidics, AI-driven image analysis, and nano-dispensing technologies to enable high-throughput and precise isolation and cloning of individual cells. It is designed to accelerate gene therapy development by ensuring monoclonality, a critical regulatory requirement, while reducing processing timelines from weeks to days. Additionally, the system supports CRISPR-based gene editing by enabling efficient delivery of editing components to target cells, thereby advancing next-generation therapeutic development.

In January 2025, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, acquired Poseida Therapeutics Inc. for $1.5 billion. With this acquisition, Roche aims to enhance its gene transplant and cell therapy portfolio by gaining access to Poseida’s proprietary non-viral gene editing and delivery technologies for the treatment of genetic disorders and cancers. Poseida Therapeutics Inc. is a US-based pharmaceutical company engaged in developing gene transplant therapies.

Major companies operating in the gene transplant market are Bayer AG, Novartis AG, CSL Behring LLC, Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., CRISPR Therapeutics AG, Beam Therapeutics Inc., Rocket Pharmaceuticals Inc., Voyager Therapeutics Inc., Sangamo Therapeutics Inc., Editas Medicine Inc., Krystal Biotech Inc., bluebird bio Inc., Orchard Therapeutics plc, 4D Molecular Therapeutics Inc., Solid Biosciences Inc., uniQure N.V., MeiraGTx Holdings plc.

North America was the largest region in the gene transplant market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene transplant market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene transplant market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the gene transplant market by increasing costs of imported viral vectors, bioprocessing equipment, single-use consumables, and advanced laboratory instruments used in gene therapy development. Biotechnology companies and hospitals in North America and Europe are most affected due to reliance on imported biomanufacturing components, while Asia-Pacific faces higher costs for export-oriented production. These tariffs are increasing therapy development expenses and slowing scale-up timelines. However, they are also encouraging domestic biomanufacturing investments, regional supply chain development, and localized production of gene therapy materials.

The gene transplant market research report is one of a series of new reports that provides gene transplant market statistics, including gene transplant industry global market size, regional shares, competitors with a gene transplant market share, detailed gene transplant market segments, market trends and opportunities, and any further data you may need to thrive in the gene transplant industry. This gene transplant market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene transplant refers to the technique of introducing healthy or modified genes into a patient’s cells to replace or repair defective genes responsible for disease. Its main objective is to treat genetic disorders, restore normal cellular function, or deliver therapeutic benefits, such as enhancing the immune system’s ability to target diseases.

The primary types of gene transplant are autologous and allogeneic. Autologous refers to a therapeutic method in which a patient’s own cells are collected, genetically modified, and transplanted back into the same patient to treat or prevent disease. It is applied in genetic disorders, cancer, rare diseases, and other conditions, serving end-users such as hospitals, research institutes, biotechnology companies, and others.

The gene transplant market includes revenues earned by entities through gene therapy consultation, genetic engineering, cell processing and modification, vector delivery services, clinical trial support, and patient-specific treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.